Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension
Status:
Completed
Trial end date:
2020-01-08
Target enrollment:
Participant gender:
Summary
This is the long-term open label extension (OLE) of the study PRISMA-3 (NCT03160521). Those
patients who complete participation in the main segment of the study (double blind) together
with other clinically stable not previously enrolled (de novo patients) may opt to
participate in this extension segment, where they will receive active Risperidone ISM® (75 mg
or 100 mg)under open-label conditions every four weeks for approximately 12 months.